BiotechTube

HSK21542 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pruritus

Conditions

Pruritus

Trial Timeline

Sep 16, 2021 → Aug 3, 2022

NCT ID
NCT04999787

About HSK21542 + Placebo

HSK21542 + Placebo is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT04999787. Target conditions include Pruritus.

What happened to similar drugs?

0 of 6 similar drugs in Pruritus were approved

Approved (0) Terminated (1) Active (5)
🔄MR13A9 + PlaceboKissei PharmaceuticalPhase 3
🔄Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
🔄HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
❌5 mg Serlopitant TabletsVyne TherapeuticsPhase 3
🔄5mg Serlopitant Tablets + Placebo TabletsVyne TherapeuticsPhase 3
🔄5mg Serlopitant Tablets + Placebo TabletsVyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT05135390Phase 3Completed
NCT04999787Phase 2Completed
NCT04738357Phase 3Completed
NCT04110886Phase 1Completed

Competing Products

20 competing products in Pruritus

See all competitors
ProductCompanyStageHype Score
Nalmefene + PlaceboTharimmunePhase 2
32
SHR0410Jiangsu Hengrui MedicinePhase 1
29
SHR0410 + PlaceboJiangsu Hengrui MedicinePhase 1
25
DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mgNovartisPhase 2
35
MR13A9 + PlaceboKissei PharmaceuticalPhase 3
40
MR13A9 + PlaceboKissei PharmaceuticalPhase 2
35
GabapentinPfizerPre-clinical
22
Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
47
BLU-5937 + PlaceboGSK plcPhase 2
35
Dupilumab 300Mg Solution for InjectionRegeneron PharmaceuticalsPhase 2
35
REGN846Regeneron PharmaceuticalsPhase 1/2
24
Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kgHaisco Pharmaceutical GroupPhase 2
35
HSK21542 tablet + PlaceboHaisco Pharmaceutical GroupPhase 2
31
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
40
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
32
Nalbuphine HCL ERTrevi TherapeuticsPhase 1
23
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
32
VLY-686 + PlaceboVanda PharmaceuticalsPhase 2
25
VLY-686 + PlaceboVanda PharmaceuticalsPhase 1
19
Serlopitant + PlaceboVyne TherapeuticsPhase 2
17